Distribution Agreement will Bring Select CBD and Curaleaf Hemp to the Caribbean , Latin America and Travel Retail
– Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf”) a leading international provider of consumer CBD and hemp products, today announced that its Select CBD and Curaleaf Hemp products will become available for the first time in the Caribbean market thanks to a new distribution agreement with WB Canna Co. & Wellness (“WB Canna Co.”). This agreement will bring Curaleaf’s lineup of products from its eponymous Hemp and Select CBD product lines to customers in, and traveling throughout, the U.S. Virgin Islands Puerto Rico Aruba Bermuda Barbados Cayman, Costa Rica Guatemala Jamaica and Saint Maarten, as well as additional markets in Latin America travel retail, and the cruise and diplomatic channel.
WB Canna Co. & Wellness is a wholly owned subsidiary of Miami -based WEBB Banks, the leading premium wine and spirits distributor in the Caribbean and one of the first companies in the region focused on distribution of top-quality CBD and wellness products. The distribution relationship combines Curaleaf’s expertise in creating high-quality non-psychoactive hemp products with WB Canna Co.’s ability to navigate the legal and compliance needs across the fragmented geography of the Caribbean , bringing operating efficiencies that will drive further accessibility to Curaleaf’s family of CBD products.
Curaleaf Hemp offers a broad range of CBD products with consumer-friendly formats and price points to select retailers throughout the U.S. A collection of all-new Select CBD products that feature minor cannabinoids like CBN and CBG, are slated to debut in April. All Curaleaf and Select CBD products are subjected to stringent industry testing practices.
“We are committed to setting the highest possible standards for product quality and accessibility at Curaleaf, and we are thrilled to expand the reach of our award-winning CBD products to retail stores in the Caribbean through a distribution partner like WB Canna Co. It continues to be of utmost importance that we’re able to provide consumers with reliable access to the products they know and love,” said Patrick Larkin , SVP of Sales at Curaleaf.
“We believe that consumer demand for high-quality CBD products will continue to grow year-over-year, and we remain laser-focused on building brand recognition and brand loyalty,” said Joseph Gennaro , VP of CBD, Health & Wellness at Curaleaf. “Consequently, our agreement with WB Canna Co. marks a key inflection point in the go-to-market strategy for our CBD business and shows our commitment to achieving international growth.”
“In the short time since launching WB Canna Co. and Wellness early last year, we’ve seen incredible interest and excitement for high-quality CBD and wellness products throughout the Caribbean and Latin America ,” said Phillip Jarrell , COO of WB Canna Co. & Wellness. “We’re very proud to add Curaleaf to our growing portfolio and introduce their popular and innovative products to consumers across the region.”
CBD products that are derived from hemp contain less than 0.3% THC and have been legal at the federal level since the passing of the Farm Bill in 2018. As a precaution, we recommend researching the CBD laws and regulations of your destination, as well as any countries or states you are traveling through en route to your destination. You should also thoroughly understand the products in your possession, and whether they contain any THC or are purely CBD. TSA rules apply. The statements above have not been evaluated by the U.S. Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
For more information, please visit CuraleafHemp.com and SelectCBD.com.
About Curaleaf Holdings
Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf”) is a leading international provider of consumer products in cannabis with a mission to improve lives by providing clarity around cannabis and confidence around consumption. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf and Select, provide industry-leading service, product selection and accessibility across the medical and adult-use markets. In the United States , Curaleaf currently operates in 23 states with 128 dispensaries, 26 cultivation sites, and employs over 5,600 team members. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Canadian Securities Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com .
About WB Canna Co. & Wellness
WB Canna Co. & Wellness, a wholly owned subsidiary of Miami -based WEBB Banks, distributes top-quality cannabidiol (CBD) and wellness products in the Caribbean , Latin America , and Travel Retail. The portfolio includes well-known brands and category leaders including Curaleaf, cbdMD, Marley, Dream Water, and Secret Nature, with additional top brands to be announced soon.
FORWARD-LOOKING STATEMENTS
This media advisory contains forward–looking statements and forward–looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, “expects” or, “proposed”, “is expected”, “intends”, “anticipates”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward–looking statements and information concerning Curaleaf’s business relationship with WB Canna Co. & Wellness and hemp products related thereto. Such forward-looking statements and information reflect management’s current beliefs and are based on assumptions made by and information currently available to the company with respect to the matter described in this new release. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information about these assumptions and risks and uncertainties is contained under “Risk Factors and Uncertainties” in the Company’s latest annual information form filed March 9, 2022 , which is available under the Company’s SEDAR profile at http://www.sedar.com , and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.
INVESTOR CONTACT
Curaleaf Holdings, Inc.
[email protected]
MEDIA CONTACTS
Curaleaf Holdings, Inc.
Tracy Brady , VP Corporate Communications
[email protected]
WB Canna Co. & Wellness
Greg Cohen
[email protected]
View original content: https://www.prnewswire.com/news-releases/curaleaf-signs-agreement-with-wb-canna-co–wellness-301523580.html
SOURCE Curaleaf Holdings, Inc.
News Provided by PR Newswire via QuoteMedia

Ayurcann Holdings Corp. (CSE: AYUR) (OTCQB: AYURF) (FSE: 3ZQ0) (” Ayurcann ” or the ” Corporation “), a leading Canadian cannabis extraction company specializing in the processing and co-manufacturing of pharma grade cannabis and hemp to produce various derivative cannabis 2.0 and 3.0 products in the medical and recreational market, is pleased to announce that it has grown its distribution to 1,000 with its vapes and tinctures products in Canada .

Ayurcann has been on fire with its best-selling Fuego vapes in every province it has entered. Now, having crossed its 1,000 ^th distribution point and with the introduction of new brands such as Bravo6, Xplor, Her Highness, Hustle & Shake, Joints, and Vida coming to market, Ayurcann is growing its exposure and market share throughout the country. The right product, the right value and access to a growing group of retailers in NB, ON, MB, AB, SK keeps Ayurcann on a continuous path of profitability and growth.
The Company is also pleased to announce the grant of stock options (each an ” Option “) and restricted share units (each an ” RSU “) pursuant to the Company’s stock option plan and restricted share unit plan, respectively.
The Company has granted an aggregate of 133,233 Options and an aggregate of 821,500 RSUs to certain directors, officers, employees, and consultants of the Company. Each Option is exercisable at a price of $0.17 per common share, expires three years from the date of grant and vests immediately. Each Option is exercisable to purchase one common share in the capital of the Company.
Each RSU granted vests immediately. All of the RSUs (and any common shares issuable upon redemption) will be subject to a four month and one day hold period pursuant to the polices of the Canadian Securities Exchange (” CSE “) and applicable securities laws.
Ayurcann is a leading post-harvest solution provider with a focus on providing and creating custom processes and pharma grade products for the adult use and medical cannabis industry in Canada . Ayurcann is striving to become a partner of choice for leading Canadian and international cannabis brands by providing best-in-class, proprietary services including extraction, formulation, product development and custom manufacturing.
Neither the CSE nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
This news release contains “forward-looking statements” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking statements. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: Ayurcann growing its exposure and market share throughout the country; Ayurcann maintaining a continuous path of profitability and growth; and the ability of the Corporation to become the partner of choice for leading Canadian cannabis brands.
Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Corporation will expand and be able to maintain production capacity; the Corporation’s ability to continue as a going concern; continued approval of the Corporation’s activities by the relevant governmental and/or regulatory authorities; the continued growth of the Corporation; the Corporation’s successful implementation of its strategy to expand market share in extract and extract derivatives while providing exceptional products to consumers ; the Corporation’s continuing ability to meet the requirements necessary to remain listed on the CSE and alternative exchanges; Ayurcann growing its exposure and market share throughout the country; Ayurcann maintaining a continuous path of profitability and growth; and the Corporation becoming the partner of choice for leading Canadian cannabis brands.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the Corporation’s inability to expand and/or maintain production capacity; the potential inability of the Corporation to continue as a going concern; the risks associated with the cannabis industry in general; increased competition in the cannabis extraction market; the potential future unviability of the cannabis market; risks associated with potential governmental and/or regulatory action with respect to the cannabis industry; the Corporation’s inability to obtain continued regulatory approvals ; the Corporation’s inability to successfully implement its strategy to expand market share in extract and extract derivatives while providing exceptional products to consumers ; the Corporation’s inability to meet the requirements necessary to remain listed on the CSE and alternative exchange; the Corporation’s inability to grow its exposure and market share; the Corporation being unable to maintain a continuous path of profitability and growth; and the inability of the Corporation to become the partner of choice for leading Canadian cannabis brands.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions, or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Corporation’s expectations as of the date hereof and are subject to change thereafter. The Corporation undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events, or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.
SOURCE Ayurcann Holdings Corp.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2022/12/c2089.html
News Provided by Canada Newswire via QuoteMedia

Trading resumes in:
Company: Numinus Wellness Inc.
TSX Symbol: NUMI
All Issues: Yes
Resumption (ET): 8:00 AM
IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada .
SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

View original content: http://www.newswire.ca/en/releases/archive/April2022/12/c2879.html
News Provided by Canada Newswire via QuoteMedia

Numinus Wellness Inc. (“Numinus“, the “Company”) (TSX: NUMI) (OTCQX: NUMIF) and Novamind Inc. (“Novamind”) (CSE: NM) (OTCQB: NVMDF) (FSE: HN2), are pleased to announce that they have entered into a definitive arrangement agreement (the “Agreement”) pursuant to which Numinus will acquire all of the issued and outstanding common shares of Novamind (the “Novamind Shares”) in an all-share transaction, by way of a court-approved plan of arrangement, for total consideration of approximately C$26.2 million on a fully diluted in-the-money basis (the “Transaction”).
Following the Transaction, the combined company will operate 13 wellness clinics and will be positioned as a leading psychedelic-assisted therapy provider in North America , leading its peer group in revenue with approximately C$10 million in annual pro-forma revenue based on the trailing four quarters.
“Since Numinus began, we have always strived to be the most trusted, evidence-based leader in psychedelic-assisted therapy and medicine. The Novamind acquisition presents a transformational opportunity for Numinus to launch a strong U.S. platform through eight established, reputable, efficiently operating and revenue-producing clinics,” says Payton Nyquvest , Founder and CEO, Numinus. “We prioritize working with the best partners in this industry and Novamind’s U.S. market presence, complementary client programming and respected clinical research capabilities allow us to accelerate our strategic growth plans and broaden access to healing and wellness.”
Mr. Nyquvest continued: “We expect this acquisition will significantly bolster our financial performance, growing Numinus‘ annual revenue to more than five times our current levels, and driving meaningful margin improvement through identified operating efficiencies. Our combined capabilities will deliver exceptional value for our clients, employees, and shareholders. We look forward to welcoming the Novamind team to the Numinus family.”
Yaron Conforti , CEO and Co-Founder, Novamind, said, “This transaction offers significant value for Novamind’s shareholders and provides compelling new opportunities for our employees, patients and research partners. The combination of Novamind’s network of mental health clinics and research sites in the U.S. and Numinus‘ leadership in psychedelic-assisted psychotherapy in Canada creates a best-in-class company. The combined entity is supported with over C$50 million in pro-forma capital and positioned with distinct capabilities to serve a growing and diverse group of stakeholders. We are excited to join Numinus, a true leader in mental health innovation.”
Proposed Transaction
Under the terms of the Agreement, shareholders of Novamind (“Novamind Shareholders”) will receive 0.84 of a common share of Numinus (the “Exchange Ratio”) for each Novamind share held, implying an offer price of $0.44 per Novamind Share. The offer price represents a premium of 51% to Novamind’s 20-day volume-weighted average price (“VWAP”) on the Canadian Securities Exchange (the “CSE”) as of April 8, 2022 . After giving effect to the Transaction, Novamind Shareholders will hold ~18% ownership in the pro-forma company (on a fully diluted in-the-money basis).
Key Transaction Highlights
Clinic Leadership
The combined company will operate 13 wellness clinics in focused geographies across the U.S. and Canada , and will continue developing and scaling innovative psychedelic therapy protocols and procedures for screening, preparation, dosing and integration targeting difficult-to-treat mental health conditions, including post-traumatic stress disorder (PTSD), COVID-19 burnout, depression, addiction and eating disorders. Operationally, the combined company will benefit from a centralized client care center for managing client inquiries, scheduling clients with appropriate providers, coordinating physician referral intakes, fulfilling prescription requests and facilitating insurance authorizations. The company’s Utah clinics have secured approval for direct billing of intravenous (IV) ketamine for treatment-resistant depression from four major health insurance providers.
Research Leadership
The combined company will operate four clinical research sites and a bioanalytical laboratory, all of which are currently supporting leading drug developers in psychedelic medicine with critical infrastructure and services. Select ongoing psychedelic medicine clinical trials include:
The combined company will benefit from drug developers’ high R&D spend and offers unprecedented capabilities for psychedelic clinical research from pre-clinical studies through phase IV trials.
Pro-Forma Financial Information:
C$ from the last four
reported quarters
Numinus
(Trailing 4 quarters ended
Nov. 30, 2021)
Novamind
(Trailing 4 quarters ended
December 31, 2021)
Combined
(Pro-Forma)
Revenue
$2,074,099
$7,906,423
$9,980,522
Gross Profit
$7,562
$3,777,296
$3,784,858
Gross Profit Margin
0.4%
47.8%
37.9%
Cash
$53.9 million
(as at Nov. 30, 2021)
$2.7 million
(as at Dec. 31, 2021)
$56.6 million
Additional Transaction Information
Key Novamind personnel have entered into employment agreements that will become effective on closing, and/or will enter into non-competition, non-solicitation and standstill agreements on closing.
Numinus‘ executive team and board will remain in place, with the Company being led by CEO Payton Nyquvest .
Completion of the Transaction is subject to a number of conditions including the receipt of regulatory, TSX and CSE approvals. Pursuant to TSX and CSE rules, the Transaction must also be approved by both Numinus‘ and Novamind’s shareholders. Following anticipated shareholder approvals, the Transaction is expected to close in June 2022 , at which point all Novamind operations will transition to Numinus branding.
Cozen O’Connor LLP is serving as legal counsel and Eight Capital is acting as financial advisor to Numinus. McMillan LLP is acting as legal counsel to Novamind.
Special Meetings and Information Circulars
Numinus will be convening a special meeting of its shareholders to consider the Transaction. Numinus currently anticipates that the special meeting will be held in early June 2022 and that an information circular containing additional details regarding the business of the special meeting will be mailed to shareholders in mid-May.
Novamind will be convening a special meeting of its shareholders to approve the Transaction. Novamind currently anticipates that the special meeting will be held in early June 2022 and that an information circular containing additional details regarding the business of the special meeting will be mailed to shareholders in mid-May.
Boards of Directors Recommendation and Voting Support
The arrangement has been unanimously approved by the boards of directors of both Numinus and Novamind (with an interested director abstaining). Directors and officers of Novamind holding in aggregate 31% of the outstanding Novamind Shares, have entered into customary voting and support agreements to, amongst other things, vote in favour of the arrangement at the special meeting of Novamind shareholders to be held to consider the transaction.
Eight Capital is acting as financial advisor to Numinus‘ board of directors. The board of directors, based upon their investigations, concluded that the Transaction is in the best interests of Numinus shareholders, and will be recommending that shareholders vote in favour of a resolution at the special meeting of shareholders.
Clarus Securities has provided a fairness opinion to Novamind’s board of directors (the “Novamind Board”) and a special committee of independent directors of the Novamind Board (the “Novamind Special Committee”) formed to, among other things, review and evaluate the terms of the Transaction and has provided its opinion that, as of the date of the opinion and subject to the assumptions and limitations contained in such opinion, Numinus‘ offered price is fair, from a financial point of view, to Novamind. The Novamind board of directors, based upon, among other things, their investigations and the recommendation of the Novamind Special Committee, including their consideration of that fairness opinion concluded that the Transaction is in the best interests of Novamind shareholders, and will be recommending that shareholders vote in favour of a resolution at its special meeting of shareholders.
Investor Presentation and Conference Call
A presentation for the investment community with highlights of the Transaction will be available on Numinus‘ investor relations website at: https://www.investors.numinus.com/events-and-presentations
Highlights of the Transaction will also be discussed on Numinus‘ upcoming Q2 2022 results conference call, occurring at 5:30 pm ET / 2:30 pm PT on Thursday , April 14, 2022.
To listen to the live webcast, please register at: https://event.on24.com/wcc/r/3723657/8A7C51BC48923FC18A54C2754EF10DBA
The webcast will also be archived on the Events and Presentations page of Numinus‘ Investor Relations website: https://www.investors.numinus.com/events-and-presentations
To participate in the live conference call, please use the following dial-in information:
1 (888) 330-3632 (Toll-free North America )
1 (646) 960-0837 (International)
Please ask to participate in Numinus‘ Q2 2022 Results Call. To avoid any delays in joining the call, please dial in at least five minutes prior to the call start time. If prompted, please provide conference passcode 3547386.
About Numinus
Numinus Wellness (TSX: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.
Learn more at www.numinus.com and follow us on LinkedIn , Facebook , Twitter , and Instagram .
About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of integrative mental health clinics and operates a full-service contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca .
Forward-Looking Statements
This news release includes certain “forward‐looking information” and “forward‐looking statements” (collectively “forward‐looking statements”) within the meaning of applicable Canadian securities legislation, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. All statements in this news release that address events or developments that the Company expects to occur in the future are forward‐looking statements. Forward‐looking statements are statements that are not historical facts and are often identified by words such as “expect”, “plan”, “anticipate”, “project”, “target”, “potential”, “schedule”, “forecast”, “budget”, “estimate”, “intend” or “believe” and similar expressions or their negative connotations, or that events or conditions “will”, “would”, “may”, “could”, “should” or “might” occur, and include information regarding: (i) expectations regarding whether the proposed Transaction will be consummated, including whether conditions to the consummation of the Transaction will be satisfied, or the timing for completing the Transaction and receiving the required securityholder, regulatory and court approvals, (ii) the anticipated timing of the securityholder meeting of the Company and the mailing of the information circular in respect of the meeting; (iii) expectations regarding the potential benefits of the Transaction and the ability of the combined company to successfully achieve business objectives; and (iv) expectations for other economic, business, and/or competitive factors.
Forward‐looking statements necessarily involve assumptions, risks and uncertainties, certain of which are beyond the Company’s control. These forward‐looking statements are qualified in their entirety by cautionary statements and risk factor disclosure contained in filings made by the Company with the Canadian securities regulators, including the Company’s financial statements and related MD&A for the financial year ended August 31, 2021 and its interim financial statements and related MD&A for the three months ended November 30, 2021 , all filed with the securities regulatory authorities in all provinces and territories of Canada , except Québec, and available under the Company’s profile at www.sedar.com . The risk factors are not exhaustive of the factors that may affect the Company’s forward‐looking statements. The Company’s forward‐looking statements are based on the applicable assumptions and factors management considers reasonable as of the date hereof, based on the information available to management of the Company at such time.  The Company does not assume any obligation to update forward‐looking statements if circumstances or management’s beliefs, expectations or opinions should change other than as required by applicable securities laws. There can be no assurance that forward‐looking statements will prove to be accurate, and actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward‐looking statements. Accordingly, undue reliance should not be placed on forward‐looking statements.
View original content: https://www.prnewswire.com/news-releases/numinus-to-acquire-novamind-creating-the-north-american-industry-leader-in-psychedelic-therapy-and-research-301523397.html
SOURCE Numinus Wellness Inc.

View original content: http://www.newswire.ca/en/releases/archive/April2022/12/c0779.html
News Provided by Canada Newswire via QuoteMedia

As chatter about cannabis legalization below the border heats up, when will Canadian producers be able to tap into the opportunity in the booming US marketplace?
Operators in Canada have for the most part fallen out of favor, thanks in large part to poor financial results and a clear ceiling on what the domestic market can offer — especially compared to opportunities for US stocks.
While Canadian companies have targets in their sights and are talking about what their plays in the US could be, experts are cautioning market participants about the realities of the market.
Here the Investing News Network (INN) breaks down what’s ahead for Canada-based cannabis operators in desperate need of US opportunities.
Thanks to the notoriously hype-heavy conditions of the cannabis space, investors have long banked on the possibility of Canadian companies entering the US at some point in the future.
When dialogue surrounding reform or legalization efforts in the US ramps up, Canadian stocks tend to go on significant share price runs based on the promise of one day accessing the territory below the border.

But ultimately confusion persists about how soon Canadian companies will be permitted entry — as investors know, the political process surrounding cannabis in the US has been challenging, with many ups and downs.
While the recent MORE Act vote has sparked optimism about federal legalization in the US, the financial experts INN has spoken with believe it’s still not in sight. They are finding it difficult to get excited about a Canadian takeover in the US, particularly when the market is already flooded with operators.
Aside from that, Charles Taerk, CEO of Faircourt Asset Management, explained that even if federal cannabis policy changes, it still won’t be a simple process for Canadians to go to the US.
“It’s not as easy as just saying, ‘Well now it’s federal, game on!’ because that’s only step one,” he explained. “Let’s just say that tomorrow the US is legal — the Canadian companies would be on the outside looking in. Because even if there was federal legislation, they don’t have any state licenses to operate.”
Taerk also acts as one of the fund managers for the Ninepoint Alternative Health Fund, which regularly has cannabis names within its top holdings. “People are forgetting that there’s been hundreds of millions of dollars, if not billions, spent … building cultivation and dispensaries and processing facilities in different states,” he said.
Even so, as attention shifts from domestic sales in Canada to the fractured — but still ocean-sized — US opportunity, some Canadian cannabis operators are set on approaching plant-touching ventures in the country.
Currently the one open opportunity for companies with senior listings lies in the expanding hemp-derived CBD market, which Canadians can enter freely thanks to laws permitting the business of derivatives from hemp. Canadians have also attempted stake claims into the US market by way of M&A activity with an eye for the future.
“Even in the perfect world where US legalization happens, the Canadians would be far behind their US counterparts,” Taerk told INN. “I’m not sure that the Canadians would be tough competition.”
Matt Carr, chief trends strategist at the Oxford Club, told INN he wasn’t surprised to see Canadian cannabis companies receive trading attention in the lead-up to the MORE Act vote.
“(Canadian operators) are the ones that are easily accessed through platforms like Robinhood (NASDAQ:HOOD), where you don’t have any sort of special approvals to do, (you don’t have to do) over-the-counter trading,” he explained. “Everybody’s going to be rushing into those.”
Carr also believes the long-term outlook for the recent legalization bill is not as green as the market wants it to be.
“I do not think this session, especially with the midterm elections in the US on the horizon, that legalization — federal legalization — is going to happen at the moment,” he said. “But it is coming.”
Other experts have also told INN they expect the MORE Act to stall in the Senate again due to partisanship. It previously got stuck there after making it through the House back in December 2020.
However, some financial advisors have expressed enthusiasm about how MORE Act discussions could impact the SAFE Banking Act, which is attempting to make life a bit easier for publicly traded cannabis operators.
“There’s a lot more support for some type of federal reform for cannabis really coming from both sides of the aisle, more than at any point in the past,” Dan Ahrens recently told INN. Ahrens is managing director and chief operating officer at AdvisorShares Investments, as well as manager of two cannabis exchange-traded funds.
The SAFE Banking Act is a promising policy aiming to ease the financial business restrictions on US-based cannabis companies. It is expected that if this legislation were to clear Congress it would allow US companies to move their listings to more prominent US-based stock exchanges.
“But the SAFE Act does not support decriminalization or legalization of cannabis,” Nawan Butt, a portfolio manager with Purpose Investments, reminded investors when speaking to INN.
The investment expert was bullish on US operators long before they overtook Canadian companies in promise and market outlook. “There’s no near-term upside that we see for these Canadian companies vs. the US,” Butt said.
Expectations are changing for Canadian cannabis companies.
While they were once expected to expand from territory to territory, using their expertise and capital to grow, now they are facing stiff competition from their already established US counterparts.
Still, market research firm New Frontier Data is now projecting that sales of cannabis will reach US$72 billion by 2030, meaning growth opportunities continue to exist. This figure may compel Canadian companies with money and a solid vision to stick with their plans of taking a run at the plant-touching US market.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.
Acquires High-Performing Medical Dispensary Located in Cumberland, MD
Valuation Represents 5X 2021 EBITDA with Significant Projected Profitability Growth in 2022
TerrAscend Corp. (“TerrAscend” or the “Company”) (CSE: TER) (OTCQX: TRSSF), a leading North American cannabis operator, today announced that it has entered into a definitive agreement to acquire Allegany Medical Marijuana Dispensary (“AMMD”), a medical dispensary in Maryland from Moose Curve Holdings, LLC (“Moose Curve”). Under the terms of the agreement, TerrAscend will acquire 100% equity interest in AMMD for total consideration of US$10 million in cash, in addition to acquiring the real estate for US$1.7 million (the “Transaction”). The Transaction is subject to customary closing conditions and regulatory approvals.
Located near interstate 68 and close to the West Virginia and Pennsylvania borders at 100 Beall St, Cumberland, MD 21502, AMMD has built a strong and loyal customer base in Northwestern Maryland . TerrAscend expects to rebrand the 8,000 square foot dispensary as The Apothecarium, the Company’s award-winning retail dispensary concept. In addition, TerrAscend will be supplying the dispensary with its own high-quality branded products, including Gage, Kind Tree and Valhalla edibles, subject to regulatory approval. Following the close of the Transaction, TerrAscend’s retail footprint will increase to 27 dispensaries nationwide.
“Our Maryland strategy is coming together nicely,” said Jason Wild , Executive Chairman of TerrAscend. “When we entered the state, we planned to significantly expand our cultivation and manufacturing capacity, in addition to vertically integrating. One year later we have made significant progress, with the buildout of our 160,000 square foot facility and our acquisition of this high performing medical dispensary.”
Mr. Wild added, “Our progress is especially exciting within the context of the recent news that adult-use will be on the ballot in the November election. I could not be happier about how well positioned we are for the possible launch of Maryland’s adult use program in mid-2023.”
TerrAscend is a leading North American cannabis operator with vertically integrated operations in Pennsylvania , New Jersey , Michigan and California , licensed cultivation and processing operations in Maryland and licensed production in Canada . TerrAscend operates The Apothecarium and Gage dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. TerrAscend’s cultivation and manufacturing practices yield consistent, high-quality cannabis, providing industry-leading product selection to both the medical and legal adult-use markets. The Company owns several synergistic businesses and brands, including Gage Cannabis, The Apothecarium, Ilera Healthcare, Kind Tree, Prism, State Flower, Valhalla Confections, and Arise Bioscience Inc. For more information, visit www.terrascend.com .
This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.
Actual results and developments may differ materially from those contemplated by these statements. Such forward-looking statements are based on certain assumptions regarding expected growth, results of operations, performance, industry trends and growth opportunities. These assumptions may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements.
Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to, current and future market conditions; risks related to federal, state, provincial, territorial, local and foreign government laws, rules and regulations, including federal and state laws in the United States relating to cannabis operations in the United States ; and the risk factors described in our Registration Statement on Form 10 and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov , and other filings with Canadian securities regulators, including TerrAscend’s management information circular dated October 4, 2021 , and TerrAscend’s most recently filed MD&A, both filed with the Canadian securities regulators and available under TerrAscend’s profile on SEDAR at www.sedar.com .
The statements in this press release are made as of the date of this release. TerrAscend disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
SOURCE TerrAscend

View original content: http://www.newswire.ca/en/releases/archive/April2022/11/c2454.html
News Provided by Canada Newswire via QuoteMedia

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES.
Hempsana Holdings Ltd. (the ” Company ” or ” Hempsana “) a leader in the production and refinement of cannabinoids and manufacturing of Cannabis 2.0 products, is pleased to announce with GAMA Corp (” GAMA “) a contract manufacturing agreement with Caviar Gold Brand to bring the original infused and the only patented brand in the world pre-roll cones and moon rocks to the Canadian and International Markets for both the recreational and medical market.
“We are extremely excited to team up with Cavi Mike and his Caviar Gold, Ice Cube and Jay & Silent Bob brands to deliver their patented high quality high potency infused products to Canada. The Caviar Gold brand continues to dominate the infused pre-roll cone and moon rock categories across multiple states in the USA, and now is the right time to share these brands in Canada and abroad,” said Randy Ko, Chief Executive Officer of Hempsana.
Caviar Gold Brands have differentiated and set their products apart from all other infused flower brands using a proprietary extraction process and an innovative unique finishing process for their infused products. Hempsana and GAMA expect to begin initial production of Caviar Gold’s portfolio of infused pre-rolls and moon rocks in Q2 of 2022 with launch dates of the products and distribution to retail stores across Canada to commence in the second half of 2022. The product portfolio will include, but not limited to, one gram infused pre-roll cones and moon rocks in one-gram and two-gram sizes for the following strains:
About Hempsana Holdings Ltd.
The Company’s business involves the manufacturing of major and minor cannabinoid derivatives and producing cannabis extracts for use in finished products and other infused consumables. Hempsana‘s Health Canada Standard Processing Licensed, and EU-GMP compliant facility provides the Company access to wholesale and retail channels in Canada and internationally. Hempsana currently offers a wide range of product formats, including cannabis concentrates, diamonds, tablets, topicals, tinctures, salves, infused pre-rolls, and hemp-based CBD products that are all manufactured and distributed by Hempsana.
About GAMA Corp.
The Company’s business involves consulting on the formulation and stabilization of major and minor cannabinoid derivatives and partnering with Licensed producers to deliver contract manufacturing operational (CMO) services for existing power brands out of the United States and unique products that are in high demand and short supply in Canada and International markets.
About Caviar Gold Brand
Caviar Gold Brand is a cannabis products processor that utilizes patented processes to infuse full spectrum THC into premium quality cannabis flower, to produce the one of the most potent (up to 58% THC) and smokable pre-rolls and moon rocks in the market. Along with its award-winning line up of Caviar Gold Products, Caviar Gold Brand manufacturers customized formulations for internationally recognized Celebrities such as Ice Cube, Jay & Silent Bob brands at this time. Currently, products are available in many states including: California, Nevada, Arizona, Colorado, Michigan and Oklahoma, with several additional states coming online in 2022.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements and forward-looking information within the meaning of applicable Canadian and U.S. securities laws. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify forward-looking information or statements. More particularly and without limitation, this press release contains forward looking statements and information concerning the business and operations of the Company. The forward-looking statements and information are based on certain key expectations and assumptions made by management, including expectations and assumptions concerning the Company. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information. There can be no assurance that they will prove to be correct. By its nature, such forward-looking information is subject to various risks and uncertainties, which could cause the actual results and expectations to differ materially from the anticipated results or expectations expressed. These risks and uncertainties, include, but are not limited to, general economic conditions and the state of the regulatory environment. Please refer to the Company’s public record on SEDAR at www.sedar.com for more details on the risks faced by the Company. Readers are cautioned not to place undue reliance on this forward-looking information, which is given as of the date hereof, and to not use such forward- looking information for anything other than its intended purpose. Management of the Company undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005280/en/
For additional information regarding Hempsana, please contact:
Randy Ko
Director and Chief Executive Officer
T: (647) 255-8849
E: [email protected]
News Provided by Business Wire via QuoteMedia

Investing News Network websites or approved third-party tools use cookies. Please refer to the  cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies. 

source